SCHEMBL8513840

SCHEMBL8513840

O=c1c2cnc(Nc3ccc(C4CCCCN4)cc3)nc2nc2c3ccccc3n(-c3ncccn3)n12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.40
CDK4 P11802 7/20 0.39
WEE1 P30291 5/20 0.39
CDK6 Q00534 4/20 0.39
AURKA O14965 1/20 0.35
CCND1 P24385 3/20 0.34
CCND2 P30279 3/20 0.34
CCND3 P30281 3/20 0.34
PLK1 P53350 1/20 0.34
MEN1 O00255 2/20 0.34
CYP2D6 P10635 2/20 0.34
CYP2C19 P33261 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8514433 0.83 WEE1 (0.53) WEE1PLK1KCNH2
SCHEMBL8510512 0.78 CCND3 (0.40) PTK2CDK4WEE1CDK6CCND1
SCHEMBL8509910 0.78 WEE1 (0.42) WEE1PLK1KCNH2
SCHEMBL8513220 0.77 CAMK2D (0.43) WEE1AURKAKCNH2CCNA2CDK2
SCHEMBL214554 0.77 WEE1 (0.53) CDK4WEE1CDK6CCND1CCND2
SCHEMBL216994 0.77 WEE1 (0.48) WEE1PLK1
SCHEMBL8513235 0.77 WEE1 (0.42) CDK4WEE1CDK6CCND1PLK1
SCHEMBL188193 0.77 CAMK2D (0.41) WEE1CYP1A2KCNH2CDK1CCNA2
SCHEMBL8510633 0.77 ADRA2A (0.46) WEE1PLK1
SCHEMBL8512238 0.77 ADRA2A (0.46) WEE1PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-8288396-B2 Pyrimidopyrimidoindazole derivative MSDKK (JP) 2012-10-16 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE MSD K.K. (JP) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120134955-A1 PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE WEE1, WEE2, DCK PTK2 86/4885CDK4 52/4885WEE1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.